Literature DB >> 20957377

AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.

Valérie Vingtdeux1, Peter Davies, Dennis W Dickson, Philippe Marambaud.   

Abstract

Tauopathies represent a class of neurodegenerative disorders characterized by abnormal tau phosphorylation and aggregation into neuronal paired helical filaments (PHFs) and neurofibrillary tangles. AMP-activated protein kinase (AMPK) is a metabolic sensor expressed in most mammalian cell types. In the brain, AMPK controls neuronal maintenance and is overactivated during metabolic stress. Here, we show that activated AMPK (p-AMPK) is abnormally accumulated in cerebral neurons in 3R+4R and 3R tauopathies, such as Alzheimer's disease (AD), tangle-predominant dementia, Guam Parkinson dementia complex, Pick's disease, and frontotemporal dementia with parkinsonism linked to chromosome 17, and to a lesser extent in some neuronal and glial populations in the 4R tauopathies, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease. In AD brains, p-AMPK accumulation decorated neuropil threads and dystrophic neurites surrounding amyloid plaques, and appeared in more than 90% of neurons bearing pre-tangles and tangles. Granular p-AMPK immunoreactivity was also observed in several tauopathies in apparently unaffected neurons devoid of tau inclusion, suggesting that AMPK activation preceded tau accumulation. Less p-AMPK pathology was observed in PSP and CBD, where minimal p-AMPK accumulation was also found in tangle-positive glial cells. p-AMPK was not found in purified PHFs, indicating that p-AMPK did not co-aggregate with tau in tangles. Finally, in vitro assays showed that AMPK can directly phosphorylate tau at Thr-231 and Ser-396/404. Thus, activated AMPK abnormally accumulated in tangle- and pre-tangle-bearing neurons in all major tauopathies. By controlling tau phosphorylation, AMPK might regulate neurodegeneration and therefore could represent a novel common determinant in tauopathies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20957377      PMCID: PMC3060560          DOI: 10.1007/s00401-010-0759-x

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  42 in total

1.  A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease.

Authors:  G A Jicha; E Lane; I Vincent; L Otvos; R Hoffmann; P Davies
Journal:  J Neurochem       Date:  1997-11       Impact factor: 5.372

2.  Nutritional status, cognition, and survival: a new role for leptin and AMP kinase.

Authors:  Yossi Dagon; Yosefa Avraham; Iddo Magen; Arie Gertler; Tamir Ben-Hur; Elliot M Berry
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

3.  A caspase cleaved form of tau is preferentially degraded through the autophagy pathway.

Authors:  Philip J Dolan; Gail V W Johnson
Journal:  J Biol Chem       Date:  2010-05-13       Impact factor: 5.157

4.  Resveratrol stimulates AMP kinase activity in neurons.

Authors:  Biplab Dasgupta; Jeffrey Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-16       Impact factor: 11.205

Review 5.  AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.

Authors:  D Grahame Hardie
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

6.  AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism.

Authors:  Valérie Vingtdeux; Luca Giliberto; Haitian Zhao; Pallavi Chandakkar; Qingli Wu; James E Simon; Elsa M Janle; Jessica Lobo; Mario G Ferruzzi; Peter Davies; Philippe Marambaud
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

Review 7.  Autophagy, amyloidogenesis and Alzheimer disease.

Authors:  Ralph A Nixon
Journal:  J Cell Sci       Date:  2007-12-01       Impact factor: 5.285

Review 8.  Neuropathology of non-Alzheimer degenerative disorders.

Authors:  Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2009-08-25

9.  AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation.

Authors:  C Culmsee; J Monnig; B E Kemp; M P Mattson
Journal:  J Mol Neurosci       Date:  2001-08       Impact factor: 2.866

10.  All-you-can-eat: autophagy in neurodegeneration and neuroprotection.

Authors:  Philipp A Jaeger; Tony Wyss-Coray
Journal:  Mol Neurodegener       Date:  2009-04-06       Impact factor: 14.195

View more
  114 in total

Review 1.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

2.  Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models.

Authors:  Christopher M Acker; Stefanie K Forest; Ray Zinkowski; Peter Davies; Cristina d'Abramo
Journal:  Neurobiol Aging       Date:  2012-06-21       Impact factor: 4.673

3.  Neuroprotective Effect of Osthole on Neuron Synapses in an Alzheimer's Disease Cell Model via Upregulation of MicroRNA-9.

Authors:  Shaoheng Li; Yuhui Yan; Yanan Jiao; Zhong Gao; Yang Xia; Liang Kong; Yingjia Yao; Zhenyu Tao; Jie Song; Yaping Yan; Guangxian Zhang; Jingxian Yang
Journal:  J Mol Neurosci       Date:  2016-07-09       Impact factor: 3.444

4.  Tau protein aggregates inhibit the protein-folding and vesicular trafficking arms of the cellular proteostasis network.

Authors:  Anan Yu; Susan G Fox; Annalisa Cavallini; Caroline Kerridge; Michael J O'Neill; Joanna Wolak; Suchira Bose; Richard I Morimoto
Journal:  J Biol Chem       Date:  2019-04-01       Impact factor: 5.157

5.  Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway.

Authors:  Lin Wang; Bing-Jin Liu; Yun Cao; Wei-Qi Xu; Dong-Sheng Sun; Meng-Zhu Li; Fang-Xiao Shi; Man Li; Qing Tian; Jian-Zhi Wang; Xin-Wen Zhou
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

Review 6.  Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer's Disease.

Authors:  Xin Wang; Helena R Zimmermann; Tao Ma
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 7.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

8.  A disruption mechanism of the molecular clock in a MPTP mouse model of Parkinson's disease.

Authors:  Akane Hayashi; Naoya Matsunaga; Hiroyuki Okazaki; Keisuke Kakimoto; Yoshinori Kimura; Hiroki Azuma; Eriko Ikeda; Takeshi Shiba; Mayumi Yamato; Ken-Ichi Yamada; Satoru Koyanagi; Shigehiro Ohdo
Journal:  Neuromolecular Med       Date:  2013-01-05       Impact factor: 3.843

9.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

10.  The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation.

Authors:  Georges Mairet-Coello; Julien Courchet; Simon Pieraut; Virginie Courchet; Anton Maximov; Franck Polleux
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.